Health Newsfeed – Johns Hopkins Medicine Podcasts Johns Hopkins Medicine

An injectable drug called omalizumab now may be used to manage severe food allergies, the FDA has decided. Robert Wood, an allergy expert at Johns Hopkins, says the drug will only work if people are taking it.

Wood: This is a therapy that will only work while you're on it. It's like our antihistamine that works while you're on it and then once you stop it it wears off, but is by no means automatically lifelong. If you want lifelong protection it's a lifelong therapy, for the family that is particularly worried about the preschool years they could use it for the preschool years and then stop it when they think their child is old enough and aware enough of their food allergy that they can practice avoidance more successfully. I actually see it rarely being used lifelong, very commonly used for these higher risk periods in people's lives.  :32

Wood says almost everyone tolerates the therapy just fine, even very young children. He’s excited to be able to offer something besides food avoidance and epinephrine in case of a reaction. At Johns Hopkins, I’m Elizabeth Tracey.

Omalizumab is an injectable drug just approved by the FDA to treat severe food allergies. Robert Wood, one author of a study used to inform the agency’s decision and an allergy expert at Johns Hopkins, says risks discerned in the study were very small, even for the youngest participants.

Wood: The other question that we discussed with our patients is what are the risks of the treatment? One of the advantages we had doing this study was that because it's an old drug there was lots of experience and knowledge about risk and they turn out to be very, very small. This drug had never been studied in anyone age 5 or under before this study and we did not see any signals for higher risk in young kids. The only warning that is on the package right now is that somewhere around one in 500 to 1000 people will have an allergic reaction to the injection itself.   :31

 Wood notes that the risk of a very severe allergic reaction to a food can include death, so for those with such allergies this can be a lifesaver. At Johns Hopkins, I’m Elizabeth Tracey.

Consequences of food allergies can be life-threatening, which is why FDA approval of omalizumab to treat them is welcome. Robert Wood, one author of a study used to inform the agency’s decision and an allergy expert at Johns Hopkins, says it’s not your imagination: food allergies are more common than they used to be.

Wood: Estimated prevalence for children it's somewhere around 8% of all kids have true food allergy. That is probably twice as high as it was 30 years ago, I'd say probably because it's hard to compare studies head-to-head, but the estimates are somewhere at least 17,000,000 Americans it's actually a little more common in adults than it is in children so we talk about you know one out of every six children in any grade school classroom have true food allergy.   :26

Wood says before this drug was approved avoidance of the foods one was allergic to was the primary means to reduce risk, and those with such allergies were advised to always carry epinephrine in case of an allergic reaction. At Johns Hopkins, I’m Elizabeth Tracey.

Feeding very young children peanut products can assure that they don’t develop an allergy to peanut. Can this strategy be expanded to allergies to foods like milk, meat, or egg? Johns Hopkins allergy expert Robert Wood comments.

Wood:  There’s an enormous market that's grown around this early introduction idea, so yes, you can buy lots of products that contain the major allergens in a form that babies can eat them. The same that's been shown for peanut is pretty clear for other allergens that early introduction could be protective. On the other hand even though the guidelines for preventing peanut allergy are now 8 years old there's been absolutely no reduction in peanut allergy. Implementing this information out into practice has not occurred.  :29

Wood says while it isn’t known precisely why the guidelines for feeding peanut have not reduced prevalence of this allergy, many believe it’s because parents don’t feed enough peanut over a long enough period of time to desensitize kids. At Johns Hopkins, I’m Elizabeth Tracey.

Can food allergies be outgrown? Elizabeth Tracey reports

Most people know about peanut allergy, since it impacts a lot of people, especially children. Can these allergies be outgrown? Robert Wood, an allergy expert at Johns Hopkins, says for most, that’s wishful thinking.

Wood: That includes everyone with peanut allergy, everyone with tree nut allergies. The odds are 80 to 90% that they will not. The odds are 70-80% they will outgrow something like a milk or egg allergy but the 20 or 30% who don't persist all the way into adulthood with these very severe allergies for foods that are hard to avoid. We've done lots of studies on the natural history of these allergies and have some pretty good markers of likelihood of being outgrown or not.    :26

Wood is one author of a recent study demonstrating the efficacy of omalizumab, an injectable drug used for asthma, in controlling food allergies in the majority of people in the study, including children younger than five years of age. The drug controls food allergies broadly but also seasonal allergies and asthma for most. At Johns Hopkins, I’m Elizabeth Tracey.

If you have a severe allergy to one food, you probably have the same issues with other foods, as well as allergies to things like pollen that you inhale. That’s according to Robert Wood, principal investigator on a study that demonstrates the efficacy of a drug called omalizumab in managing these multiple allergies and an allergy expert at Johns Hopkins.

Wood: Virtually all of our patients with food allergy have other forms of allergy and most have allergic rhinitis and asthma. While this drug was only approved for severe asthma it works incredibly well for all levels of asthma so if you have a family where they're on the fence should I start this drug or not to think there's a possibility that they could that one shot that would treat all those things is pretty amazing and truly can treat all of those things.  :25

Wood says omalizumab binds to an antibody our bodies produce when we are allergic to something called IgE. While our bodies make many unique antibody molecules, all of those of the IgE subclass are bound by omalizumab, which is why it can help control the full range of allergic conditions. At Johns Hopkins, I’m Elizabeth Tracey.